Astex Pharmaceuticals, Inc. Message Board
-
My timing sucks!LOL.......If I was to wait another day to buy the stock at 7.62, there my 40 cents gain this morning when I have plenty of time to sell them @8.03.
Mets1p, told you not to fret over SanDisk when you bought @58 and change. Over your target sale around the low 60.
Tomorrow if the Market cooperates, Achillion will tack on another 25 cents from today close.Sentiment: Strong Buy
-
Those were the ones bought @6.82 and 7.08. Market Makers will have their way with the June 7.50 Options. Gamble on next Tuesday presentation to see a bump in share price so I bought back in today. Exact amount of shares sold last Friday. Towards September time frame is when I will hold on to those trading shares. Core position still intact.
Sentiment: Strong Buy
-
@7.81. Expect 40 cents gain next week.
Sentiment: Strong Buy
-
@ least the company is presenting in one of them. Expect another pop in share price!
Sentiment: Strong Buy
-
Jason S Fisherman bought 10,000 shares @7.87 on 06/03/13.
Sentiment: Strong Buy
-
On 6/3/2013, Dennis Liotta bought another 20,000 shares @7.90. Great confidence shown by him.
Sentiment: Strong Buy
-
Not selling those trading shares this time around as I want to see the Data on Sovaprevir+3102+ Rbv this Summer and later on the Data on the amended trial without Rbv.
Sentiment: Strong Buy
-
The Street has always been critical about the company not having a Nucleoside based prodrug. No more excuse as the in-house expertise for developing nuc based compound dated back Elvucitabine for HBV and HIV. Someone likes the outlook as 10,000 January 2014 10 call was bought this morning (that's translate into 1 million shares). I have lost twice playing options here ( short term ) but in the money now for the 7.50 January 2014 calls.
Sentiment: Strong Buy
-
with Ach-3422, a Uridine Nuc Prodrug.....all in-house discovery which in time would complement the company portfolio of PIs and NS5A. Off to the Race!
Sentiment: Strong Buy
-
Kishbauch is not leaving the company but is taking on a more important role as Chairman of the newly formed Strategy and Corporate development Committee of the Board. He is leaving the day to day operation to Deshpande. Still very much involve in decision making with the board of directors. A changing of the guards is a good thing. Lastly you don't bring people from ex-pharmasset and for them to take a position in the company for nothing.
Being said, it's all comes down to how well the Data of Sovaprevir+3102+Rbv will show this summer and the amended trial for those without Ribavirin.Sentiment: Strong Buy
-
giguy,
Best of Luck to you too. -
JB,
Honesty, Hard Work and Humbleness go a long way. May your endeavor bear fruition someday. -
Need stronger volume to blast through next resistance @7.93.
Sweet buy @6.82 a few weeks back!Sentiment: Strong Buy
-
They let the post goes through this time.
-
This time. Yahoo's automatic spam filter is getting out of hands!LOL. So I am trying to format the link differently. Worth every minute to watch this. How was Achillion's phase 2a End of treatment fro the 58 patients stacked up to the latest @ the 2013 easl meeting. I said not bad at all.
'newcmedotcom/andrew-j-muir-md-hcv-best-easl-2013/'.
Dr. Andrew Muir also commented on the single DAA pilot trial of ach-3102+rbv.
Keep the price low and I will keep accumulate those dirt cheap shares.Sentiment: Strong Buy
-
Both FMR and QVT increase their stakes. Most notably is Baker Brothers who according to their 13 F filing bought 455,000 shares of this company. BB made it big by investing in the early days in Pharmasset.
Sentiment: Strong Buy
-
If Achillion had 11 billions to spend, they wouldn't be behind would they?. If you go back to April 23 of last year and read the Clarification on 12 weeks End of treatment; Achillion isn't that far behind. Back then, the company stated they have treated over 158 HCV infected patients, Naive and Experienced. Trial 007 has a good chance to produce results in the 95 to 100 percentile. Still holding firm to my core position and trading the trough.
Sentiment: Buy
-
There won't be any M&A by Gilead nor any of the Pharma companies someone mentioned before. 007 trial results will make or break this Company. Management also needs to advance 2684 into other genotypes and show good Data. Any chance of a buyout rely heavily on those outcomes. Timeline, November of this year (AASLD) and into the 2014 JP Morgan Health Conference. If there is a merger or buyout; it would come from a Japanese Pharmaceutical.
Sentiment: Buy
-
No chance to post the rest as tried before!
Sentiment: Buy
-
I agree with both of you. The Interim result of 1625+3102+rbv needs to be in the 95 percentile for Achillion to have a place in the HepC arena. Anything less, look out below. Don't have to wait long. Third Q is when the Data on RVR, SVR and cEVR are made public. But based on the clarification dated back in April of 2012 End of Treatment Data From Phase 2a Trial With ACH-1625 Based Regimen in Hepatitis C; there is a good chance for those numbers. See if Yahoo would allow me to post the tabulated Data:
ACH-1625
Segment 2: 12-week treatment
duration assessments 200 mg
n=19 400 mg
n=20 800 mg
n=19
RVR (HCV RNA